EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

We studied whether electroencephalography (EEG)-derived measures of brain oscillatory activity are related to clinical progression in nondemented, amyloid positive subjects. We included 205 nondemented amyloid positive subjects (63 subjective cognitive decline [SCD]; 142 mild cognitive impairment [MCI]) with a baseline resting-state EEG data and ≥1-year follow-up. Peak frequency and relative power of 4 frequency bands were calculated. Relationships between normalized EEG measures and time to clinical progression (conversion from SCD to MCI/dementia or from MCI to dementia) were analyzed using Cox proportional hazard models. One hundred eight (53%) subjects clinically progressed after 2.1 (IQR 1.3–3.0) years. In the total sample, none of the EEG spectral measures were significant predictors. Stratified for baseline diagnosis, we found that in SCD patients higher delta and theta power (HR [95% CI] = 1.7 [1.0–2.7] resp. 2.3 [1.2–4.4]), and lower alpha power and peak frequency (HR [95% CI] = 0.5 [0.3–1.0] resp. 0.6 [0.4–1.0]) were associated with clinical progression over time. In amyloid positive subjects with normal cognition, slowing of oscillatory brain activity is related to clinical progression.

Original languageEnglish
Pages (from-to)133-142
Number of pages10
JournalNeurobiology of Aging
Volume57
DOIs
Publication statusPublished - 1 Sep 2017

Cite this

@article{430a585ed1a94a95809a6850e8607054,
title = "EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects",
abstract = "We studied whether electroencephalography (EEG)-derived measures of brain oscillatory activity are related to clinical progression in nondemented, amyloid positive subjects. We included 205 nondemented amyloid positive subjects (63 subjective cognitive decline [SCD]; 142 mild cognitive impairment [MCI]) with a baseline resting-state EEG data and ≥1-year follow-up. Peak frequency and relative power of 4 frequency bands were calculated. Relationships between normalized EEG measures and time to clinical progression (conversion from SCD to MCI/dementia or from MCI to dementia) were analyzed using Cox proportional hazard models. One hundred eight (53{\%}) subjects clinically progressed after 2.1 (IQR 1.3–3.0) years. In the total sample, none of the EEG spectral measures were significant predictors. Stratified for baseline diagnosis, we found that in SCD patients higher delta and theta power (HR [95{\%} CI] = 1.7 [1.0–2.7] resp. 2.3 [1.2–4.4]), and lower alpha power and peak frequency (HR [95{\%} CI] = 0.5 [0.3–1.0] resp. 0.6 [0.4–1.0]) were associated with clinical progression over time. In amyloid positive subjects with normal cognition, slowing of oscillatory brain activity is related to clinical progression.",
keywords = "Alzheimer's disease, Amyloid beta, Clinical progression, Electroencephalography, Prognostic biomarker",
author = "Gouw, {Alida A.} and Alsema, {Astrid M.} and Tijms, {Betty M.} and Andreas Borta and Philip Scheltens and Stam, {Cornelis J.} and {van der Flier}, {Wiesje M.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.neurobiolaging.2017.05.017",
language = "English",
volume = "57",
pages = "133--142",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",

}

EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. / Gouw, Alida A.; Alsema, Astrid M.; Tijms, Betty M.; Borta, Andreas; Scheltens, Philip; Stam, Cornelis J.; van der Flier, Wiesje M.

In: Neurobiology of Aging, Vol. 57, 01.09.2017, p. 133-142.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects

AU - Gouw, Alida A.

AU - Alsema, Astrid M.

AU - Tijms, Betty M.

AU - Borta, Andreas

AU - Scheltens, Philip

AU - Stam, Cornelis J.

AU - van der Flier, Wiesje M.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - We studied whether electroencephalography (EEG)-derived measures of brain oscillatory activity are related to clinical progression in nondemented, amyloid positive subjects. We included 205 nondemented amyloid positive subjects (63 subjective cognitive decline [SCD]; 142 mild cognitive impairment [MCI]) with a baseline resting-state EEG data and ≥1-year follow-up. Peak frequency and relative power of 4 frequency bands were calculated. Relationships between normalized EEG measures and time to clinical progression (conversion from SCD to MCI/dementia or from MCI to dementia) were analyzed using Cox proportional hazard models. One hundred eight (53%) subjects clinically progressed after 2.1 (IQR 1.3–3.0) years. In the total sample, none of the EEG spectral measures were significant predictors. Stratified for baseline diagnosis, we found that in SCD patients higher delta and theta power (HR [95% CI] = 1.7 [1.0–2.7] resp. 2.3 [1.2–4.4]), and lower alpha power and peak frequency (HR [95% CI] = 0.5 [0.3–1.0] resp. 0.6 [0.4–1.0]) were associated with clinical progression over time. In amyloid positive subjects with normal cognition, slowing of oscillatory brain activity is related to clinical progression.

AB - We studied whether electroencephalography (EEG)-derived measures of brain oscillatory activity are related to clinical progression in nondemented, amyloid positive subjects. We included 205 nondemented amyloid positive subjects (63 subjective cognitive decline [SCD]; 142 mild cognitive impairment [MCI]) with a baseline resting-state EEG data and ≥1-year follow-up. Peak frequency and relative power of 4 frequency bands were calculated. Relationships between normalized EEG measures and time to clinical progression (conversion from SCD to MCI/dementia or from MCI to dementia) were analyzed using Cox proportional hazard models. One hundred eight (53%) subjects clinically progressed after 2.1 (IQR 1.3–3.0) years. In the total sample, none of the EEG spectral measures were significant predictors. Stratified for baseline diagnosis, we found that in SCD patients higher delta and theta power (HR [95% CI] = 1.7 [1.0–2.7] resp. 2.3 [1.2–4.4]), and lower alpha power and peak frequency (HR [95% CI] = 0.5 [0.3–1.0] resp. 0.6 [0.4–1.0]) were associated with clinical progression over time. In amyloid positive subjects with normal cognition, slowing of oscillatory brain activity is related to clinical progression.

KW - Alzheimer's disease

KW - Amyloid beta

KW - Clinical progression

KW - Electroencephalography

KW - Prognostic biomarker

UR - http://www.scopus.com/inward/record.url?scp=85021055963&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2017.05.017

DO - 10.1016/j.neurobiolaging.2017.05.017

M3 - Article

VL - 57

SP - 133

EP - 142

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

ER -